{"id":146,"date":"2013-10-23T01:14:44","date_gmt":"2013-10-23T01:14:44","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/?p=146"},"modified":"2017-08-21T13:11:52","modified_gmt":"2017-08-21T13:11:52","slug":"primary-care-corner-with-geoffrey-modest-md-influenza-2013","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2013\/10\/23\/primary-care-corner-with-geoffrey-modest-md-influenza-2013\/","title":{"rendered":"Primary Care Corner with Geoffrey Modest MD: Influenza 2013"},"content":{"rendered":"

see below. mmwr on influenza control. i felt proud to know that one of the influenza strains covered by the vaccine is from massachusetts.\u00a0 we finally made it.<\/p>\n

you can click on the link to read the whole article. just a couple of changes:<\/p>\n

–Boston added!<\/p>\n

–several new formulations, including quadrivalent, egg-free (for ages 18-49 only).\u00a0 we only have the trivalent at the health center at this point<\/p>\n

there was info a couple of years ago suggesting deceasing efficacy of the live attenuated vaccine (LAIV) vs inactivated as people reach the ripe old age of around 35-40. (i don\u2019t have that reference). not mentioned in \u00a0\u00a0mmwr. there was an article comparing vaccines (see DOI:10.1111\/j.1750-2659.2010.00183.x) which suggested that the live vaccine may be more effective as a priming vaccine and the TIV more effective in boosting pre-existing immunity.\u00a0 which could explain the age difference (if it is real). i personally stopped using the LAIV in patients over late 30\u2019s because of the data from a few years ago, but since not mentioned in MMWR, probably it is okay to use it.<\/p>\n

 <\/p>\n

geoff<\/p>\n

 <\/p>\n

From:<\/b> Centers for Disease Control & Prevention [mailto:cdc@service.govdelivery.com<\/a>]
\nSent:<\/b> Thursday, September 19, 2013 12:19 PM
\nTo:<\/b> Modest, Geoffrey A.,M.D.
\nSubject:<\/b> MMWR Vol. 62 \/ No. RR-7<\/p>\n

 <\/p>\n

\n\n\n\n
Having trouble viewing this email? View it as a Web page<\/a>.<\/p>\n

 <\/p>\n\n\n\n\n
\n

If you have trouble reading this e-mail, please click here.<\/a><\/p>\n<\/td>\n<\/tr>\n

\n\n\n\n\n\n
\n

\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Recommendations and Reports<\/i><\/strong>
\nVolume 62, No. RR-7<\/strong>
\nSeptember 20, 2013<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/td>\n<\/tr>\n
\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/tr>\n
PDF of this issue<\/a><\/strong><\/p>\n

MMWR Online<\/a><\/strong><\/p>\n

Subscriptions<\/a><\/strong><\/p>\n

Contact MMWR<\/a><\/strong><\/p>\n

CDC Homepage<\/a><\/strong><\/td>\n<\/tr>\n

<\/strong>MMWR<\/b><\/em> RSS Feed<\/strong>
\n<\/b>How to Add MMWR<\/em> RSS feeds<\/a>
\nLearn More About RSS<\/a><\/td>\n<\/tr>\n
\n

\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n

\n\n\n\n\n\n\n\n\n\n
\n

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization<\/strong>
\nPractices <\/strong><\/b>\u2014<\/strong> United States, <\/strong>
\n2013<\/strong><\/b>\u2013<\/strong>2014<\/strong><\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

\n<\/td>\n

<\/td>\n<\/tr>\n
\n

This report updates the 2012 recommendations by CDC\u2019s Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccines for the prevention and control of seasonal influenza. Routine annual influenza vaccination is recommended for all persons aged \u22656 months. For the 2013\u201314 influenza season, it is expected that trivalent live attenuated influenza vaccine (LAIV3) will be replaced by a quadrivalent LAIV formulation (LAIV4). Inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Vaccine virus strains included in the 2013\u201314 U.S. trivalent influenza vaccines will be an A\/California\/7\/2009 (H1N1)\u2013like virus, an H3N2 virus antigenically like the cell-propagated prototype virus A\/Victoria\/361\/2011, and a B\/Massachusetts\/2\/2012\u2013like virus. Quadrivalent vaccines will include an additional influenza B virus strain, a B\/Brisbane\/60\/2008\u2013like virus, intended to ensure that both influenza B virus antigenic lineages (Victoria and Yamagata) are included in the vaccine. This information is intended for vaccination providers, immunization program personnel, and public
\nhealth personnel.<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

full text<\/a><\/p>\n<\/td>\n

<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/td>\n<\/tr>\n
 <\/td>\n<\/tr>\n
\n

\nDepartment of Health and Human Services<\/strong>
\nCenters for Disease Control and Prevention<\/strong><\/b><\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n
\n
\n

\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n <\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n
 <\/td>\n<\/tr>\n
STAY CONNECTED:<\/td>\n<\/tr>\n
 <\/td>\n<\/td>\n\u00a0CDC on Facebook<\/a><\/td>\n<\/td>\n\u00a0Dr. Frieden on Twitter<\/a><\/td>\n<\/td>\n\u00a0CDC on YouTube<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n
\n<\/div>\n\n\n\n
This email was sent to gmodest@partners.org<\/a> using GovDelivery, on behalf of: Centers for Disease Control and Prevention (CDC) \u00b7 1600 Clifton Rd \u00b7 Atlanta, GA 30333 \u00b7 1-800-CDC-INFO (800-232-4636)<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Influenza control […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":148,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14283],"tags":[],"class_list":["post-146","post","type-post","status-publish","format-standard","hentry","category-archive"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/148"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=146"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/146\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}